A Comparative Efficacy and Safety Study of Long-Acting Risperidone Injection and Risperidone Oral Tablets Among Hospitalized Patients: 12-Week Randomized, Single-Blind Study

Objective: The superiority of risperidone long-acting injection (RLAI) over oral typical and atypical antipsychotics demonstrated in previous studies may be related to the improved drug compliance. The aim of the 12-week randomized, single-blind study was to test whether the superiority of RLAI remained among hospitalized patients that drug compliance could be optimally controlled. Methods: Fifty hospitalized stable schizophrenic patients, who had maintained on oral risperidone for more than 3 months, were randomized to the RLAI and oral risperidone group. Finally 49 patients (98 %) completed the study, and no dose change of oral risperidone, or RLAI was noted among all patients. Results: The RLAI group showed significantly increased positive score of Positive and Negative Syndrome Scale (PANSS) than the risperidone group (0.72 ± 3.52 vs. –1.24 ± 3.81, p = 0.022), but without significance difference for the PANSS total, negative and general psychopathology scores. The RLAI group also showed a significantly improved Udvalg for Kliniske Undersogelser (UKU) Scale (p = 0.037), social life domains of Short-From Health Survey (SF-36) (p = 0.011), and reduced prolactin level (p = 0.001). Conclusion: The results indicated that with optimal controlling of drug compliance among hospitalized patients, RLAI showed no benefit of efficacy over oral risperidone, but with advantages of improved side-effect profiles, social life ratings, and reduced prolactin levels.

References

• 1 Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C, Weiden P J. Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-1696
• 2 Andreasen N C, Carpenter WT J r, Kane J M, Lasser R A, Marder S R, Weinberger D R. Remission in schizophrenia: proposed criteria and rationale for consensus.  . 2005;  162 441-449
• 3 Baptista T, Kin N M, Beaulieu S, de Baptista E A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.  . 2002;  35 205-219
• 4 Bhanji N H, Chouinard G, Margolese H C. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.  Eur Neuropsychopharmacol. 2004;  14 87-92
• 5 Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?.  J Clin Psychiatry. 2001;  62 855-859
• 6 Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David A S. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.  Eur Neuropsychopharmacol. 2005;  15 111-117
• 7 Eerdekens M, Van H I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.  Schizophr Res. 2004;  70 91-100
• 8 Fleischhacker W W, Eerdekens M, Karcher K, Remington G, Llorca P M, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.  J Clin Psychiatry. 2003;  64 1250-1257
• 9 Fleischhacker W W, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.  Br J Psychiatry 2005. Aug ;  187 131-136
• 10 Hay J. Complications at site of injection of depot neuroleptics.  BMJ. 1995;  311 421
• 11 Hosalli P, Davis J M. Depot risperidone for schizophrenia. Cochrane Database Syst Rev 2003: CD004161
• 12 Kane J M, Eerdekens M, Lindenmayer J P, Keith S J, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.  Am J Psychiatry. 2003;  160 1125-1132
• 13 Keith S J, Kane J M, Turner M, Conley R R,  N asrallahHA. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics.  . 2004;  65 120-131
• 14 Kropp S, Ziegenbein M, Grohmann R, Engel R R, Degner D. Galactorrhea due to psychotropic drugs.  . 2004;  37 (Suppl 1) S84-88
• 15 Lane H Y, Chang Y C, Chiu C C, Lee S H, Lin C Y, Chang W H. Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.  Psychopharmacology (Berl). 2004;  172 393-399
• 16 Lasser R A, Bossie C A, Gharabawi G M, Kane J M. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.  Schizophr Res. 2005 Sep 15;  77 (2 – 3) 215-227
• 17 Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone.  Pharmacoepidemiol Drug Saf. 2004;  13 811-816
• 18 Lindenmayer J P, Eerdekens E, Berry S A, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.  J Clin Psychiatry. 2004;  65 1084-1089
• 19 Liu C Y, Chiu N Y, Wu C K, Yuan L M, Hsiao M C, Liao O. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.  Int Clin Psychopharmacol. 2003;  18 49-51
• 20 Masand P S, Gupta S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.  Drugs Aging. 2003;  20 1099-1110
• 21 Mendhekar D N, Jiloha R C, Srivastava P K. Effect of risperidone on prolactinoma--a case report.  . 2004;  37 41-42
• 22 Nasrallah H A, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.  J Clin Psychiatry. 2004;  65 531-536
• 23 Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner M S, Medori R, Gaebel W. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.  . 2005;  19 (Suppl 5) 5-14
• 24 Sim K, Su A, Leong J Y, Yip K, Chong M Y, Fujii S, Yang S, Ungvari G S, Si T, Chung E K, Tsang H Y, Shinfuku N, Kua E H, Tan C H. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study.  Pharmacopsychiatry. 2004;  37 175-179
• 25 van Os J, Bossie C A, Lasser R A. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.  Int Clin Psychopharmacol. 2004;  19 229-232